Funding search · EIN 223744037 · Madison, NJ
Kaleidoscope of Hope Foundation
A grantmaking public charity (files IRS Form 990, Schedule I). Charities like this often run real grant programs with application cycles.
- 7
- grants reported
- $250,000
- total given
- 2022–2023
- filing years
- $25,000
- median grant
Based on grants this organization reported to the IRS for tax years 2022–2023. This is what they filed, not a complete record of their giving, and recent years may be incomplete because filings lag.
Funder website ↗Full IRS filings ↗How this is builtReport an error
Funding pattern
What this funder pays for, at what size, and how to position adjacent work. Read from their filings, with every number checked against the record.
Sign in to analyze this funder’s giving pattern. Free in early access.
7 grants matching “ovarian” · $250,000
- $50,000
Trustees of the Univeristy of Pennsylvania · Philadelphia, PA · 2023
Investigation of a novel p53 stabilizing targeted treatment combination in tp53 wild type ovarian cancer.
- $50,000
Temple University - of the Commonwealth System of Higher Education · New York, NY · 2023
Understanding the role of carm 1 in regulation of cytokine-mediated antitumor response in ovarian cancer.
- $25,000
Stevens Institute of Technology · Hoboken, NJ · 2023
Nutritional supplement taurine suppresses ovarian cancer.
- $25,000
University of Texas Md Anderson Cancer Center · Houston, TX · 2023
To identify liquid biopsy (extracellular vesicles)based molecular predictors of disease patterns from patients from matched tissues and blood from patients with complete gross resection and patients with excellent and p… read allTo identify liquid biopsy (extracellular vesicles)based molecular predictors of disease patterns from patients from matched tissues and blood from patients with complete gross resection and patients with excellent and poor response to chemotherapy, followed by clinical vallidation of our finding in patients with highgrade serous ovarian cancer. less
- $50,000
Women & Infant Hospital of Rhode Island · Providence, RI · 2022
Determine spatially resolved immune responses to chemotherapy in high grade serous ovarian cancer and determine levels of serum lag3, pd1, icos, and ox40 throughout the course of chemotherapy treatment and whether they … read allDetermine spatially resolved immune responses to chemotherapy in high grade serous ovarian cancer and determine levels of serum lag3, pd1, icos, and ox40 throughout the course of chemotherapy treatment and whether they correlate with patient clinical outcomes. less
- $25,000
Trustees of the University of Pennsylvania · Philadelphia, PA · 2022
Clear cell ovarian cancer (ccoc) is often resistant to standard of care chemotherapy and has limited treatment options. Dr. Xu is identifying effective treatment options for ccoc by combination of dna damarge inhibitors… read allClear cell ovarian cancer (ccoc) is often resistant to standard of care chemotherapy and has limited treatment options. Dr. Xu is identifying effective treatment options for ccoc by combination of dna damarge inhibitors and bet inhibitor, and also discovering new targets by crispr screen. With the support from koh foundation, dr. Xu will be able to have supplies and animals to continue the study and identify effective therapeutics for ccoc. less
- $25,000
University of Texas Md Anderson Cancer Center · Houston, TX · 2022
To identify liquid biopsy (extracellular vesicles)based molecular predictors of disease patterns from patients from matched tissues and blood from patients with complete gross resection and patients with excellent and p… read allTo identify liquid biopsy (extracellular vesicles)based molecular predictors of disease patterns from patients from matched tissues and blood from patients with complete gross resection and patients with excellent and poor response to chemotherapy, followed by clinical vallidation of our finding in patients with highgrade serous ovarian cancer. less
Grant history
All 7 reported grants, largest first.
- $50,000
Temple University - of the Commonwealth System of Higher Education · New York, NY · 2023
Understanding the role of carm 1 in regulation of cytokine-mediated antitumor response in ovarian cancer.
- $50,000
Trustees of the Univeristy of Pennsylvania · Philadelphia, PA · 2023
Investigation of a novel p53 stabilizing targeted treatment combination in tp53 wild type ovarian cancer.
- $50,000
Women & Infant Hospital of Rhode Island · Providence, RI · 2022
Determine spatially resolved immune responses to chemotherapy in high grade serous ovarian cancer and determine levels of serum lag3, pd1, icos, and ox40 throughout the course of chemotherapy treatment and whether they … read allDetermine spatially resolved immune responses to chemotherapy in high grade serous ovarian cancer and determine levels of serum lag3, pd1, icos, and ox40 throughout the course of chemotherapy treatment and whether they correlate with patient clinical outcomes. less
- $25,000
Stevens Institute of Technology · Hoboken, NJ · 2023
Nutritional supplement taurine suppresses ovarian cancer.
- $25,000
University of Texas Md Anderson Cancer Center · Houston, TX · 2023
To identify liquid biopsy (extracellular vesicles)based molecular predictors of disease patterns from patients from matched tissues and blood from patients with complete gross resection and patients with excellent and p… read allTo identify liquid biopsy (extracellular vesicles)based molecular predictors of disease patterns from patients from matched tissues and blood from patients with complete gross resection and patients with excellent and poor response to chemotherapy, followed by clinical vallidation of our finding in patients with highgrade serous ovarian cancer. less
- $25,000
Trustees of the University of Pennsylvania · Philadelphia, PA · 2022
Clear cell ovarian cancer (ccoc) is often resistant to standard of care chemotherapy and has limited treatment options. Dr. Xu is identifying effective treatment options for ccoc by combination of dna damarge inhibitors… read allClear cell ovarian cancer (ccoc) is often resistant to standard of care chemotherapy and has limited treatment options. Dr. Xu is identifying effective treatment options for ccoc by combination of dna damarge inhibitors and bet inhibitor, and also discovering new targets by crispr screen. With the support from koh foundation, dr. Xu will be able to have supplies and animals to continue the study and identify effective therapeutics for ccoc. less
- $25,000
University of Texas Md Anderson Cancer Center · Houston, TX · 2022
To identify liquid biopsy (extracellular vesicles)based molecular predictors of disease patterns from patients from matched tissues and blood from patients with complete gross resection and patients with excellent and p… read allTo identify liquid biopsy (extracellular vesicles)based molecular predictors of disease patterns from patients from matched tissues and blood from patients with complete gross resection and patients with excellent and poor response to chemotherapy, followed by clinical vallidation of our finding in patients with highgrade serous ovarian cancer. less
Grants already paid are the record; PaperOrbit reads your paper and finds the funders whose record matches it — then explains why.
Search funders like this oneSource: IRS Form 990, Schedule I, as filed by this organization. These are grants already paid. Grants paid directly to individuals are reported to the IRS only as totals, so they do not appear as named lines here.